Navigation Links
Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes

INDIANAPOLIS and NEW YORK, Feb. 3, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

"The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body," said Philip Larsen, M.D., Ph.D., chief scientific officer for diabetes drug discovery at Lilly. "This research is an example of regenerative medicine, a new frontier in science that replaces or regenerates new cells, tissues or organs, and while this particular research is early stage, it may ultimately lead to new approaches to treating type 1 diabetes."

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the beta cells, stopping a person's pancreas from producing insulin. Insulin is a hormone that enables people to get energy from food. According to JDRF, in the U.S. alone, as many as three million people have type 1 diabetes.(1)

One research approach to finding novel treatments for type 1 diabetes may be to restore insulin production by regenerating insulin-producing cells within a person's body. This involves triggering the body to grow its own new beta cells, either by growing existing ones – some are usually still active, even in people who have had diabetes for decades – or by creating new ones by reprogramming, which involves converting one type of cell in the body into a different type.  If a therapeutic is developed that will allow for the regeneration of beta cells, it could potentially eliminate the need for insulin.  

The JDRF-Lilly agreement will support a three-year, $1.4 million pre-clinical research effort to be led by Dr. Pedro Herrera of the University of Geneva. Previous research by Dr. Herrera showed that alpha cells in the pancreas can spontaneously, and without genetic manipulation, convert into beta cells. This suggests that alpha cell reprogramming could be a viable strategy for regenerating beta cells in people with type 1 diabetes.  

Building on this research, Dr. Herrera will collaborate with Lilly researchers to better understand these findings with the goal of translating them into potential drug targets and eventually, perhaps, even new therapies.

"As part of JDRF's focus on regeneration research, we see this collaboration as a critical opportunity to nurture new strategies to restore insulin production in people with type 1 diabetes. Previous efforts to reprogram non-beta cells into insulin-producing cells without genetic manipulation have not easily translated into therapies for type 1 diabetes," said Patricia Kilian, Ph.D., JDRF's Director of Regeneration Program.

"Collaborative research efforts like this can help address critical gaps to accelerate potentially promising research to patients," added Karin Hehenberger, M.D., Ph.D., senior vice president of Strategic Alliances for JDRF. "We seek partners who can help us deliver on our commitment to people living with diabetes, and Lilly has a long and productive history in the diabetes therapeutic space."

The agreement between JDRF and Lilly comes on the heels of a separate announcement in which Lilly and Boehinger Ingelheim said they will jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

About JDRF

JDRF is the worldwide leader for research to cure type 1 diabetes. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science world-wide.

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump - each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it pre-vent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation.

Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.5 billion to diabetes research, including $107 million last year. More than 80 percent of JDRF's expenditures directly support research and research-related education. For more information, please visit

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy  practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit


This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of preclinical research and clinical trials, the FDA and other foreign review processes and other governmental regulation, Lilly's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other factors described in Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward looking statements.

(1)  JDRF, "Type 1 Diabetes Facts" Fact Sheet February 2011,



SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
(Date:10/8/2015)... BRUNSWICK, N.J. , Oct. 9, 2015 Johnson ... of a safety and immunogenicity clinical trial in ... in development at its Janssen Pharmaceutical Companies. Trial recruitment is ... dose. This is the first study conducted of Janssen,s Ebola ... the recent Ebola epidemic. Sierra Leone,s ...
(Date:10/8/2015)... , Oct. 8, 2015  Mylan N.V. (Nasdaq: ... host a conference call and webcast on Tuesday, Oct. ... the value to be created for shareholders of Perrigo ... offer to acquire the company. During the call, Mylan ... proposition for Perrigo shareholders. Mylan,s offer represents a very ...
(Date:10/8/2015)... PHILADELPHIA , Oct. 8, 2015  Following months of ... first lawsuit in the nation alleging that the anticoagulant Xarelto,s ... with life-threatening results. Philadelphia on ... suffered an ischemic stroke because the drug didn,t work as ... to file numerous other suits shortly on behalf of clients ...
Breaking Medicine Technology:
... 24, 2011 Biomerix Corporation announced today that it ... tissue repair mesh allowing for the marketing of REVIVE ... received 510(k) clearance from the U.S. Food and Drug ... constructed of the Biomerix Biomaterial™, a proprietary, biointegrative synthetic ...
... Jan. 24, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... Bienaime, Chief Executive Officer of BioMarin, will host ... 17, at 5:00 p.m. ET to discuss fourth ... Canada Dial-in Number:  866.203.3206International Dial-in Number:  617.213.8848Participant Code: ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Each year, ... at the pre-eminent organization in global health: the World Health Organization (WHO). At ... disparities. These internships are a mechanism for WHO to help build public health ...
(Date:10/9/2015)... ... 2015 , ... Smoke alarms can save lives. In fact, according to the ... in reported home fires in half. As part of Fire Prevention Week, Amica ... and maintained. , Half of home fire deaths result from fires reported between 11 ...
(Date:10/9/2015)... Sweden (PRWEB) , ... October 09, 2015 , ... On ... Arnold Schwarzenegger World Jump Rope Championship in Madrid, Spain. Representing both the USA and ... Sprints, One-Minute Double Unders and One-Minute Am Front Crosses, she was awarded 1 Silver ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the ... walks of life to save money on the high cost of their prescription ... per medication, individuals and families can receive their medications delivered direct from over ...
(Date:10/9/2015)... ... October 09, 2015 , ... Deadly, record-smashing rainfall has ... Foundation (CCCF) in Columbia, South Carolina. In response, the Foundation has established a ... – both short and long term. 100% of monies donated will go directly ...
Breaking Medicine News(10 mins):
... Oct. 28 In response to rising suicide and divorce rates ... marriages and families, will present its Weekend to Remember® ... San Diego area from Nov. 6 - 8 at The Westin ... Hyatt Regency La Jolla (3777 La Jolla Village Drive). ...
... Frederick C. Dunlap, Chairman and Chief Executive Officer of ... those with special needs, will present at the 20th ... in New York City on November 3rd. , Dunlap,s ... on XLHealth,s unique business model and strategic position as ...
... to rising suicide and divorce rates within the U.S. military, ... will present its Weekend to Remember® marriage conference ... Nov. 6 - 8 at the Hyatt Regency Milwaukee (333 ... a marriage getaway aimed at strengthening healthy marriages and healing ...
... research to examine how physicians care for patients from ... Conn., Oct. 28 Connecticut physicians believe they could ... cultural and ethnic backgrounds if they had training that ... survey released today by the Connecticut State Medical Society. ...
... Blue Shield of Florida (BCBSF) was awarded the Direct Marketing ... of the Human Voice Web site campaign. Up against thousands ... direct marketing initiative based on creativity, strategy and results. The ... San Diego on Oct. 20, hosted by former "Tonight Show" ...
... involved in tissue damage caused by smoking , WEDNESDAY, ... gene therapy for injured lungs that were previously rejected ... for transplant, researchers say. , Successful transplants require healthy ... are highly inflamed and only mildly functional, which means ...
Cached Medicine News:
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Half aprons used to protect pelvic regions...
The front of this apron is tapered for maximum adjustability as needed. We can include a specially designed half-apron to be worn under the full apron for double protection in the abdomen/pelvic cav...
... design apron has elasticized back ... comfort. Shoulder pads are standard. ... in relieving weight off the ... attained by varying the position ...
Medicine Products: